Arkolith/Insider Trading/LXEO/Form 4

See Tai Sandi

Chief Development OfficerLexeo Therapeutics, Inc. (LXEO) · full profile →Form 4 · filed Oct 17, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$35K
Net Open-Market Flow
-$35K
Transactions
3
3 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 17, 2025Sell(S)44$9.56$42166K
Oct 17, 2025Sell(S)4K$8.94$34K66K
Oct 15, 2025Grant(A)11K—$070K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002009350-25-000003) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML